p62/SQSTM1 Modulation for Inflammation and Bone Density
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammation are inadequate, as existing drugs often have side effects and are not effective in curing the condition, and there is a need for a more targeted approach to modulate inflammatory cytokines and bone resorptive factors.
Innovation Solution
Administration of a p62/SQSTM1 polypeptide or encoding nucleic acid to modulate the expression of proinflammatory cytokines, osteogenic transcription factors, and bone resorptive factors, which can be used to treat and prevent chronic inflammatory diseases by suppressing inflammatory cytokine generation and promoting bone health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-inflammatory drugs are used to treat chronic inflammation, then inflammation symptoms are temporarily suppressed, but side effects occur and the condition is not effectively cured
Solution Approach 1:
The patent uses p62/SQSTM1 as an intermediary molecule to modulate the inflammatory response. Instead of directly suppressing inflammation with drugs that cause side effects, p62 acts as a mediator that regulates NF-κB signaling and cytokine production, providing targeted anti-inflammatory effects without the harmful side effects of conventional drugs.
Solution Approach 2:
The invention changes the therapeutic parameter from direct anti-inflammatory drug administration to administration of p62/SQSTM1 or its encoding nucleic acid. This parameter change enables modulation of inflammatory cytokine expression at the source, achieving more effective and safer treatment by altering the fundamental approach to inflammation management.
2Reliability
If conventional treatments are used for chronic inflammatory diseases, then some symptom relief is achieved, but the diseases progress and bone density continues to deteriorate
Solution Approach 1:
The patent employs a feedback mechanism where p62/SQSTM1 administration modulates the inflammatory response based on the body's own regulatory pathways. By targeting NF-κB signaling and cytokine production, the treatment creates a feedback loop that naturally suppresses inflammation and prevents bone resorption, rather than forcing suppression that leads to progression.
3Reliability
If targeted modulation of inflammatory cytokines is implemented, then disease progression is slowed, but complex delivery systems are required
Solution Approach 1:
The patent uses preliminary action by administering p62/SQSTM1 or its encoding nucleic acid before significant bone loss and disease progression occur. This preventive approach allows for easier modulation of cytokine expression and reduces the complexity of delivery systems needed, as the target pathways are more responsive to intervention at earlier stages of disease.
Data Source
AI summary
Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.